Medidata, C&R Research partner on Asian study operations, data quality
Wednesday, December 2, 2015
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, and C&R Research, a South Korean full-service CRO, have announced that the Medidata Clinical Cloud platform has been adopted to improve operational efficiencies, resource savings and decision-making processes across C&R’s entire R&D portfolio in Asia.
C&R is partnering with Medidata and leveraging its electronic data capture and management technology, as well as the company’s best-in-class solution for risk-based monitoring (RBM)—a methodology for reducing trial costs while providing a higher level of clinical data accuracy and quality.
“South Korea has quickly become a key hub for multinational clinical trials, and we at C&R are committed to ensuring we support our local and global biopharmaceutical customers’ R&D programs with the most innovative technologies,” said C&R President Moon Tae Yoon. “Partnering with a technology company that has deep life sciences expertise is essential to our success, and Medidata really understands our mission and R&D needs. The Medidata platform—which includes a holistic risk-based monitoring solution—is helping us improve operational efficiencies and decision-making processes throughout the clinical trial lifecycle, and provides us with the flexibility and scalability we need to accelerate progress across all of our clinical development programs.”
Founded in 1997 as the first CRO in South Korea, C&R provides a full range of clinical trial and regulatory affairs services. The Seoul-based organization—which specializes in oncology, biologic agents, pharmacovigilance and post-market surveillance—supports phase I-III and post-approval (phase IV to observational) clinical research. To optimize R&D operations for speed, resource saving and data quality, C&R has adopted Medidata’s cloud-based technology for electronic data capture (EDC), Medidata Rave, as its enterprise EDC solution across its entire portfolio of clinical research services. Additionally, C&R is adopting Medidata RBM, a combination of technology, analytics and hands-on strategic consulting services that enable life science organizations to quickly realize the quality, cost and timeline benefits of a comprehensive RBM program.